LCTX — Lineage Cell Therapeutics, Inc.

—
NYSE · Health Care · Biotechnology · CIK 876343 ·
Last close
$0.82
Market Cap
$206.36M
52W High
$1.99
52W Low
$0.77
ADV30
1,982,730
Next earnings
2026-11-12
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 1,434,000 1,429,000 -7,314,000 4,232,000 100,110,000 26,499,000 34,167,000
Jun 2026 1,069,000 1,069,000 -8,923,000 1,482,000 106,220,000 37,355,000 46,422,000
Mar 2026 1,725,000 1,725,000 -7,593,000 -4,812,000 109,533,000 35,939,000 56,838,000
Dec 2025 6,608,000 6,542,000 -6,548,000 851,000 112,584,000 40,791,000 69,238,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-23,816,000
Investing CF
$-13,712,000
Financing CF
$32,240,000
CapEx
$-574,000
Dividends Paid
—
Buybacks
$-41,000
EPS Diluted TTM
$-0.32
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-470,328,000
Inventory
—
Receivables
$790,000
ST Investments
$13,474,000
EBIT TTM
$-26,850,000
Pretax Income TTM
$-37,385,000
Interest Exp TTM
—
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$10,836,000
EBITDA
$-29,615,000
Free Cash Flow
$-15,393,250
Enterprise Value
$187,085,424
Total Cash
$45,176,000
Total Debt
$2,029,000
Shares Out
252,954,764
Trailing EPS
$-0.19
Book Value
$0.24
ROE
4.3%
ROA
-20.0%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 14,556,000 -21,779,000 -63,533,000 112,584,000 69,238,000 44,549,000 -18,919,000
Dec 2024 9,499,000 -21,478,000 -18,609,000 113,218,000 36,206,000 78,381,000 -23,092,000
Dec 2023 8,945,000 -24,733,000 -21,486,000 101,019,000 38,996,000 63,419,000 -28,566,000
Dec 2022 14,703,000 -22,520,000 -26,273,000 123,664,000 51,728,000 73,339,000 1,059,000

TTM Snapshot

Revenues TTM
$13,083,000
NetIncome TTM
$-32,260,000
OpCashFlow TTM
—
Assets (Latest)
$106,220,000
Forward EPS
$-0.14

Max Pain — expiry 2027-03-19

max pain strike: $1.00 · spot: $0.84 · call oi: 2,184 · put oi: 130
Expected Move to 2027-03-19: ±$2.00 (238.52%) — implied range $-1.16 – $2.84 · ATM straddle on $1.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
DTIL PRECISION BIOSCIENCES INC $196.95M $7.05 —
IKT Inhibikase Therapeutics, Inc. $193.57M $1.38 —
CABA Cabaletta Bio, Inc. $220.03M $1.02 —
CGEN COMPUGEN LTD $191.34M $2.02 —
ARTV Artiva Biotherapeutics, Inc. $190.81M $3.86 —

News headlines (Yahoo Finance, 1h cache)

What Lineage Cell Therapeutics (LCTX) Said on Its Q3 Earnings Call
2026-11-13 08:14 · Yahoo
Lineage Cell: Q3 Earnings Snapshot
2026-11-12 21:20 · Yahoo
Lineage Cell Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-12 21:05 · Yahoo
Lineage Cell Therapeutics to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
2026-11-05 13:00 · Yahoo
Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform
2026-09-08 12:00 · Yahoo
Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript
2026-08-14 00:32 · Yahoo
Lineage Cell Therapeutics Q2 Earnings Call Highlights
2026-08-09 19:04 · Yahoo
Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
2026-07-30 12:00 · Yahoo
Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject’ Cell Therapy Plan
2026-07-14 07:02 · Yahoo
Lineage Cell Therapeutics (LCTX) Stock Faces Mixed Analyst Target Changes After Fresh Coverage
2026-06-18 16:20 · Yahoo

Recent Insider Activity

FiledTradeInsiderTitleType PriceQtyValue
2026-11-17 8:45:04 2026-11-16 Culley Brian M Pres, CEO P - Purchase 0.92 40500 37098